|
Sign In to gain access to subscriptions and/or personal tools.
|
American Journal of Alzheimer's Disease and Other Dementias®, Vol. 21, No. 2,
131-136 (2006)
DOI: 10.1177/153331750602100214
Family history of dementia does not influence the progression of Alzheimer's disease at two years: Results from the REAL.FR Study
Frédéric Cortes, DEA
Sophie Gillette-Guyonnet, PhD
Fati Nourhashemi, MD, PhD
Cantet Christelle
Bruno Vellas, MD, PhD
Service de Medecine Interne et Gerontologie Clinique, Toulouse, France
The purpose of this study was to determine whether a family history of dementia in afirst-degree relative influenced the progression of Alzheimer s disease (AD) after two years offollow-up. Patients were recruited in the REAL.FR (Reseau sur la Maladie d'Alzheimer Franqais) study and underwent behavioral, global, nutritional, and medical evaluation with assessment ofcognitivefunction and independence every six months. At inclusion, 113 patients reported a family history of dementia, and 358 patients had no family history of dementia. There was no statistical difference for any factors between the two groups at baseline. After two years offollow-up, a similar percentage of patients were still followed in each group, and although most parameters showed significant deterioration, there was no difference between the two groups, indicating that a family history of dementia does not appear to influence the progression of AD.
Key Words: Alzheimer's disease • family history of dementia • progression
References
- 1. Ott A, Breteler MM, van Harskamp F, et al.: Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study. Br MedJ. 1995; 310: 970-973.
- 2. Poirier J, Davignon J, Bouthillier D, et al.: Apolipoprotein E polymorphism and Alzheimer's disease. Lancet. 1993; 342: 697-699.[CrossRef][Medline]
[Order article via Infotrieve]
- 3. Saunders AM, Schmader K, Breitner JC, et al.: Apolipoprotein E 4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. Lancet. 1993; 342: 710-711.[CrossRef][Medline]
[Order article via Infotrieve]
- 4. van Duijn CM, Clayton D, Chandra V, et al.: Familial aggregation of Alzheimer's disease and related disorders: a collaborative reanalysis of case-control studies. EURODEM Risk Factors Research Group. Int JEpidemiol. 1991; 20(Suppl 2): S13-S20.
- 5. Huang W, Qiu C, von Strauss E, et al.: APOE genotype, family history of dementia, and Alzheimer disease risk: a 6-year follow-up study. Arch Neurol. 2004; 61: 1930-1934.[Abstract/Free Full Text]
- 6. Stern RG, Mohs RC, Davidson M, et al.: A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am JPsychiatry. 1994; 151(3): 390-396.
- 7. Rasmusson DX, Carson KA, Brookmeyer R, et al.: Predicting rate of cognitive decline in probable Alzheimer's disease. Brain Cogn. 1996;31: 133-147.[Medline]
[Order article via Infotrieve]
- 8. Gillette-Guyonnet S, Nourhashemi F, Andrieu S, et al., REAL.FR Group: The REAL.FR research program on Alzheimer's disease and its management: methods and preliminary results. J Nutr Health Aging. 2003; 7: 91-96.[Medline]
[Order article via Infotrieve]
- 9. McKhann G. Drachman D, Folstein M, et al.: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force onAlzheimer's disease. Neurology. 1984; 34: 135-146.[Free Full Text]
- 10. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: APA, 1994.
- 11. Folstein MF, Folstein SE, McHugh PR: XEN=“Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. JPsychiatric Res. 1975; 12: 189-198.
- 12. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease. Am JPsychiatry. 1984; 141: 1356-1364.
- 13. Katz S, Ford AB, Moskowitz RW, et al.: The index of ADL: A standardized measure of biological and psychosocial function. JAMA. 1963; 185: 914-919.[Medline]
[Order article via Infotrieve]
- 14. Lawton MP, Brody EM: Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969; 9: 179-186.[Medline]
[Order article via Infotrieve]
- 15. Cummings JL, Mega M, Gray K, et al.: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994; 44: 2308-2314.[Abstract/Free Full Text]
- 16. Hughes CP, Berg L, Danziger WL, et al.: A new clinical scale for the staging of dementia. Br JPsychiatry. 1982; 140: 566-572.
- 17. Vellas B, Guigoz Y, Garry PJ, et al.: The Mini Nutritional Assessment (MNA) and its use in grading the nutritional state of elderly patients. Nutrition. 1999; 2: 116-122.
- 18. Morris JC, Edland S, Clark C, et al.: The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease. Neurology. 1993; 43: 2457-2465.[Abstract/Free Full Text]
- 19. Lopez OL, Becker JT, Saxton J, et al.: Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition. JAm Geriatr Soc. 2005; 53: 83-87.[CrossRef][Medline]
[Order article via Infotrieve]
- 20. Clark CM, Sheppard L, Fillenbaum GG, et al.: Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: a clinical perspective of data from the Consortium to Establish a Registry for Alzheimer's Disease. Arch Neurol. 1999; 56: 857-862.[Abstract/Free Full Text]
- 21. Cortes F, Gillette-Guyonnet S, Nourhashemi F, et al.: Recent data on the natural history of Alzheimer's disease: results from the REAL.FR Study. JNutr Health Aging. 2005; 9: 86-93.
- 22. Gillette-Guyonnet S, Cortes F, Cantet C, et al.: Long-term cholinergic treatment is not associated with greater risk of weight loss during Alzheimer's disease: data from the French REAL.FR Cohort. J Nutr Health Aging. 2005; 9: 69-73.[Medline]
[Order article via Infotrieve]
- 23. Vellas B, Lauque S, Gillette-Guyonnet S, et al.: Impact of nutritional status on the evolution of Alzheimer's disease and on response to acetylcholinesterase inhibitor treatment. J Nutr Health Aging. 2005; 9: 75-80.[Medline]
[Order article via Infotrieve]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
|
